Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience
Background: The major effect of Exenatide is attributed to lowering of post-prandial glycemia, whereas insulin glargine mainly improves fasting glycemia [FPG]. Objective: Therefore, we assessed effect of E xenatide administration at 6 months and for at 1 year on glycemic control, lipids, body weight [BW], daily insulin dose and hypoglycemic events. Methods: Records of 164 subjects, 126 men and 38 women administered Exenatide between January 2011 and December 2013 are included in this report. Exenatide was initiated at 5 mcg subcutaneously twice daily [BID] in obese subjects, BMI > 30 kg/m 2 , with C-peptide > 1 ng/d, and HbA1c 7.5% - 9.5%, while receiving daily metformin 2000 mg, Sulfonylurea Glimepiride 8 mg and insulin Glargine [GLAR]. Exclusion criteria were creatinine > 1.5 mg/dL and liver enzymes > 2.5 times upper limit of normal. Indices of glycemic control include fasting plasma glucose levels and HbA1c. Lipids include serum concentrations of total, LDL and HDL cholesterol. Other endpoints are body weight, daily insulin dose and number of hypoglycemic events per patient during 4 weeks prior to initiation of Exenatide, at 6 months and 1 year of therapy. Results: In 37 subjects, Exenatide was discontinued within 1 - 3 weeks; 29 due to onset of nausea and vomiting. Seven of these also complained of abdominal pain and in these, serum amylase and lipase were elevated indicating presence of acute pancreatitis. One subject discontinued because of chest pain. Fasting plasma Glucose remained unchanged following Exenatide administration. However, HbA1c declined significantly denoting improvement in overall glycemic control without significant changes in body weight, daily insulin dose and hypoglycemic events. Lipid panel improved as well. Conclusion: Exenatide may be an appropriate adjuvant option in obese subjects with Type 2 diabetes mellitus with lack of desirable glycemic control while receiving therapy with Metformin, Glimepiride, and insulin Glargine. Moreover, improvement in glycemic control is likely to be secondary to lowering of post prandial hyperglycemia induced by Exenatide.
[1] Chen, Y.E. and Drucker, D. (1997) Tissue-Specific Expression of Unique mRNAs that Encode Pro-Glucagon-Derived Peptides or Exendin-4 in the Lizard. The Journal of Biological Chemistry, 272, 4108-4115.
Young, A.A., Gedulin, B.R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B. and Denaro, M. (1999) Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4: Studies in Obese Diabetic (ob/ob, dbh/db) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca mulatta). Diabetes, 48, 1026-1034. https://doi.org/10.2337/diabetes.48.5.1026
Parkes, D.G., Pittner, R., Jodka, C., Smith, P. and Young, A. (2001) Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 in Vivo and in Vitro. Metabolism, 50, 583–589. https://doi.org/10.1053/meta.2001.22519
Nielsen, L.L. and Baron, A.D. (2003) Pharmacology of Exenatide (Synthetic Exendin-4) for the Treatment of Type 2 Diabetes. Current Opinion in Investigational Drugs, 4, 401-405.
Nielsen, L.L., Young, A.A. and Parkes, D. (2004) Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Therapeutic for Improved Glycemic Control of Type Diabetes. Regulatory Peptides, 117, 77-88. https://doi.org/10.1016/j.regpep.2003.10.028
Bunck, M.C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J.L., Shaginian, R.M., Deng, W. and Kendall, D.M. (2009) One-Year Treatment With Exenatide Improves β-Cell Function, Compared with Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. Diabetes Care, 32, 762-768. https://doi.org/10.2337/dc08-1797
Szayna, M., Doyle, M.E., Betkey, J.A., Holloway, H.W., Spencer, R.G.S., Greig, N.H. and Egan, J.M. (2000) Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats. Endocrinology, 141, 1936-1941. https://doi.org/10.1210/endo.141.6.7490
Edwards, C.M., Stanley, S.A., Davis, R., Brynes, A.E., Frost, G.S., Seal, L.J., Ghatei, M.A. and Bloom, S.R. (2001) Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers. American Journal of Physiology-Endocrinology and Metabolism, 281, E155-E161. https://doi.org/10.1152/ajpendo.2001.281.1.E155
Poon, T., Nelson, P., Shen, L., Mihm, M., Taylor, K., Fineman, M. and Kim, D. (2005) Exenatide Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes: A Dose-Ranging Study. Diabetes Technology & Therapeutics, 7, 467-477.
DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. (2005) Effects of Exenatide (Exendin-4) on Glycemic Control and Weight over 30 Weeks in Metformin-Treated Patients with Type 2 Diabetes. Diabetes Care, 28, 1092-1100. https://doi.org/10.2337/diacare.28.5.1092
Blonde, L., Klein, E.J., Han, J., Zhang, B., Mac, S.M., Poon, T.H., Taylor, K.L., Trautmann, M.E., Kim, D.D. and Kendall, D.M. (2006) Interim Analysis of the Effects of Exenatide Treatment on A1C, Weight and Cardiovascular Risk Factors over 82 Weeks in 314 Overweight Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 8, 436–447. https://doi.org/10.1111/j.1463-1326.2006.00602.x
Ratner, R.E., Maggs, D., Nielsen, L.L., Stonehouse, A.H., Poon, T., Zhang, B., Bicsak, T.A., Brodows, R.G. and Kim, D.D. (2006) Long-Term Effects of Exenatide Therapy over 82 Weeks on Glycaemic Control and Weight in Over-Weight Metformin-Treated Patients with Type 2 Diabetes Mellitus. Diabetes, Obesity and Metabolism, 8, 419-428. https://doi.org/10.1111/j.1463-1326.2006.00589.x
Klonoff David, C., Buse John, B., Nielsen Loretta, L., Guan, X.S., Bowlus Christopher, L., Holcombe, J.H., Wintle Matthew, E. and Maggs, D.G. (2008) Exenatide Effects on Diabetes, Obesity, Cardiovascular Risk Factors and Hepatic Biomarkers in Patients with Type 2 Diabetes Treated for at Least 3 Years, Current Medical Research and Opinion, 24, 275-286. https://doi.org/10.1185/030079908X253870
Kolterman, O.G., Buse, J.B., Fineman, M.S., Gaines, E., Heintz, S., Bicsak, T.A., Taylor, K., Kim, D., Aisporna, M., Wang, Y. and Baron, A.D. (2003) Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 88, 3082-3089. https://doi.org/10.1210/jc.2002-021545
Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D., Exenatide-113 Clinical Study Group (2004) Effects of Exenatide (Exendin-4) on Glycemic Control over 30 Weeks in Sulfonylurea-Treated Patients with Type 2 Diabetes. Diabetes Care, 27, 2628-2635. https://doi.org/10.2337/diacare.27.11.2628
John, L.E., Kane, M.P., Busch, R.S. and Hamilton, R.A. (2007) Expanded Use of Exenatide in the Management of Type 2 Diabetes. Diabetes Spectrum, 20, 59-63. https://doi.org/10.2337/diaspect.20.1.59
American Diabetes Association (2018) Glycemic Targets: Standards of Medical Care in Diabetes. Diabetes Care, 43, S55-S64.
Louis, L.M., Lapinski, H. and Claude, C. (2003) Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients. Diabetes Care, 26, 881-885. https://doi.org/10.2337/diacare.26.3.881
Sonal, B. and Udaya, K. (2017) Eleavated Pancreatic Enzymes and Acute Pancreatitis in Subjects with Type 2 Diabetes Treated with Exenatide. Advanced Research in Gastroenterology and Hepatology, 1, 1-4.
Kabadi, U.M. and Kabadi, M.U. (2001) Improvement in Lipids with Glimepiride in Type 2 Diabetes Mellitus. Diabetes Research, 35, 155.
Kabadi, U.M. (2004) Weight Gain, Improvement in Metabolic Profiles and Immunogenicity with Insulin or Sulfonylurea Administration in AIDS. Clinical Drug Investigation, 24, 287-294. https://doi.org/10.2165/00044011-200424050-00005
Kabadi, U.M. (2006) Comparative Efficacy of Glimepiride and/or Metformin with Insulin in Type 2 Diabetes. Diabetes Research & Clinical Practice, 72, 265-270. https://doi.org/10.1016/j.diabres.2005.10.024
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., Goff Jr., D.C., Bigger, J.T., Buse, J.B., Cushman, W.C., Genuth, S., Ismail-Beigi, F., Grimm Jr., R.H., Probstfield, J.L., Simons-Morton, D.G. and Friedewald, W.T. (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. The New England Journal of Medicine, 358, 2545-2559.
Esmail, R. and Kabadi U.M. (2016) Improvement in Cardiovascular Risk Markers with Glimepiride in Non Obese Subjects with Pre Diabetes: Similar to Obese Cohort Treated with Metformin. British Journal of Medicine & Medical Research, 18, 1-6.
Fritsche, A., Schweitzer, M.A., Häring, H.U., 4001 Study Group (2003) Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes: A Randomized, Controlled Trial. Annals of Internal Medicine, 138, 952-959. https://doi.org/10.7326/0003-4819-138-12-200306170-00006
Standl, E., Maxeiner, S., Raptis, S., Karimi-Anderesi, Z., Schweitzer, M.A., HOE901/4009 Study Group (2005) Good Glycemic Control with Flexibility in Timing of Basal Insulin Supply: A 24-Week Comparison of Insulin Glargine Given Once Daily in the Morning or at Bedtime in Combination with Morning Glimepiride. Diabetes Care, 28, 419-420. https://doi.org/10.2337/diacare.28.2.419
Kabadi, U.M. (2016) Better Glycemic Control with Lesser Hypoglycemia on Transition of Insulin Glargine Administration at Bedtime to Morning in Type 2 Diabetes Mellitus. Diabetes Research and Metabolism, 1, 1-7.
Hampton, N., Exley, S., Robbins, S. and Kabadi, U.M. (2018) Lower Daily Dose with Better Outcomes with Oral Agents and AM Insulin Toujeo Administration than Lantus While Attaining Desirable Glycemic Control in Type 2 Diabetes. European Journal of Pharmaceutical and Medical Research, 5, 555-563.